1. INTRODUCTION {#acm212272-sec-0001}
===============

The Canadian Partnership for Quality Radiotherapy (CPQR) is an alliance amongst the three key national professional organizations involved in the delivery of radiation treatment in Canada: the Canadian Association of Radiation Oncology (CARO), the Canadian Organization of Medical Physicists (COMP), and the Canadian Association of Medical Radiation Technologists (CAMRT). Financial and strategic backing is provided by the federal government through the Canadian Partnership Against Cancer (CPAC), a national resource for advancing cancer prevention and treatment. The mandate of the CPQR is to support the universal availability of high quality and safe radiotherapy for all Canadians through system performance improvement and the development of consensus‐based guidelines and indicators to aid in radiation treatment program development and evaluation.

This document contains detailed performance objectives and safety criteria for *Brachytherapy Remote Afterloaders*. Please refer to the overarching document *Technical Quality Control Guidelines for Canadian Radiation Treatment Centres* [1](#acm212272-bib-0001){ref-type="ref"} for a programmatic overview of technical quality control, and a description of how the performance objectives and criteria listed in this document should be interpreted. The development of the individual TQC guidelines is spearheaded by expert reviewers and involves broad stakeholder input from the medical physics and radiation oncology community.[2](#acm212272-bib-0002){ref-type="ref"}

All information contained in this document is intended to be used at the discretion of each individual center to help guide quality and safety program improvement. There are no legal standards supporting this document; specific federal or provincial regulations and licence conditions take precedence over the content of this document.

2. SYSTEM DESCRIPTION {#acm212272-sec-0002}
=====================

Brachytherapy is the placement of encapsulated radionuclides or a miniaturized x‐ray tube in, or adjacent to, tissue which has been prescribed a radiation dose.[3](#acm212272-bib-0003){ref-type="ref"}, [4](#acm212272-bib-0004){ref-type="ref"}, [5](#acm212272-bib-0005){ref-type="ref"}, [6](#acm212272-bib-0006){ref-type="ref"}, [7](#acm212272-bib-0007){ref-type="ref"}, [8](#acm212272-bib-0008){ref-type="ref"}, [9](#acm212272-bib-0009){ref-type="ref"}, [10](#acm212272-bib-0010){ref-type="ref"} This practice offers unique advantages to the management of several treatment sites and has been used to complement or replace external beam radiation therapy since the onset of radiation oncology.

Remote afterloading equipment was developed to reduce, and in many cases eliminate, the radiation exposure to members of the staff. With remote afterloading systems the user does not directly handle the radioactive source and the patient is irradiated in a shielded room with staff operating and monitoring the process remotely.

High dose rate (HDR) refers to treatment dose rates larger than 20 cGy/min. For all HDR remote afterloaders, a single and small (\< 1 mm × 5 mm) radioactive source (mostly iridium‐192, rarely cobalt60), laser‐welded to a metallic cable, is moved out of the safe by a motor‐drive mechanism to step along the prescribed positions (dwell positions) with different irradiation times (dwell times). The user can preselect dwell positions and dwell times at selected positions in a number of applicator lines. The remote afterloader could receive up to two such sources with two independent cables permitting dose delivery in two applicator lines simultaneously. The source strength is approximately 40,000 cGy cm² h^−1^ (activity of \~370 GBq) on installation of a new iridium‐192 source, while it is of 23,000 cGy cm² h^−1^ (activity of \~74 GBq) for a new cobalt‐60 source. Because iridium‐192 has a relatively short half‐life (73.8 days), the sources are usually replaced about every 3 months. Cobalt‐60 has a longer half‐life (1 925 days or 5.27 yr), offering less frequent source replacement to every 5 yr. Typical HDR irradiation times are 5 to 30 min, and a treatment course may consist of several fractions.

Another form of treatment is pulsed dose rate (PDR) treatment. With a PDR device, irradiations are given in short "pulses" with the total treatment being given in 48 to 72 h. The mechanism for PDR units is very similar to that used in HDR units. PDR remote afterloaders also use a single iridium‐192 source attached to a cable. However, the source strength for these units is typically only 10% of the source strength of an iridium‐192 HDR unit.

High‐dose rate miniaturized x‐ray tube remote devices, along with intravascular and cardiovascular brachytherapy remote afterloaders using beta emitting radioactive sources, are beyond the scope of this document.

Various recommendations for brachytherapy quality assurance have been reported in the literature.[11](#acm212272-bib-0011){ref-type="ref"}, [12](#acm212272-bib-0012){ref-type="ref"}, [13](#acm212272-bib-0013){ref-type="ref"}, [14](#acm212272-bib-0014){ref-type="ref"}, [15](#acm212272-bib-0015){ref-type="ref"}, [16](#acm212272-bib-0016){ref-type="ref"}, [17](#acm212272-bib-0017){ref-type="ref"}, [18](#acm212272-bib-0018){ref-type="ref"} "Per treatment" tests must be executed prior to each treatment. "Treatment day" tests must be scheduled before treating the first patient of the day. For PDR remote afterloaders where treatments may last several days, "treatment day" tests should be performed prior to the initiation of the treatment.

###### 

Per treatment quality control tests

  Designator                                         Test                                                           Performance
  -------------------------------------------------- -------------------------------------------------------------- ----------------
  Per treatment (executed prior to each treatment)                                                                  
  T1                                                 Plan data transfer from treatment planning computer            Data integrity
  T2                                                 Plan dwell times adjustment                                    See note
  T3                                                 Minimum dwell times                                            See note
  T4                                                 Plan catheters' connection to remote afterloader               Reproducible
  T5                                                 Complete source retraction                                     Functional
  Treatment day (or per treatment for PDR)                                                                          
  D1                                                 Treatment interrupt                                            Functional
  D2                                                 Console displays (treatment status indicator) and key switch   Functional
  D3                                                 Date, time, and source strength in treatment unit              See note
  D4                                                 Source (and dummy) positional accuracy                         2 mm
  D5                                                 Dwell time accuracy                                            2%

John Wiley & Sons, Ltd

###### 

Quarterly quality control tests

  Designator                             Test                                                           Performance
  -------------------------------------- -------------------------------------------------------------- ----------------------
  Quarterly (or at source replacement)                                                                  
  Q1                                     Mechanical integrity of applicators, guide tubes, connectors   Functional
  Q2                                     Internal battery power supply (power failure recovery)         Functional
  Q3                                     Source/dummy interlocks                                        Functional
  Q4                                     Dummy wire positional accuracy                                 3 mm (1 mm see note)
  Q5                                     Radiological source positional accuracy                        1 mm
  Q6                                     Source strength calibration                                    5%
  Q7                                     Source homogeneity                                             Reproducible
  Q8                                     Records                                                        Complete

John Wiley & Sons, Ltd

###### 

Annual quality control tests

  Designator   Test                                                     Performance
  ------------ -------------------------------------------------------- --------------
  Annually                                                              
  A1           Hand crank operation                                     Functional
  A2           Leakage radiation                                        Reproducible
  A3           Multi‐channel indexer function                           Functional
  A4           Dwell time accuracy                                      1%
  A5           Timer linearity                                          1%
  A6           Transit time/transit dose reproducibility                Reproducible
  A7           Dosimetric length of applicators and guide tubes         1 mm
  A8           Applicators and templates dimensions                     Reproducible
  A9           Shield integrity of shielded applicators                 Reproducible
  A10          X ray marker positional accuracy                         1 mm
  A11          Document staff review of emergency response procedures   Complete
  A12          Independent quality control review                       Complete
  A13          PDR sequencing (for PDR only)                            Functional

John Wiley & Sons, Ltd

3. RELATED TECHNICAL QUALITY CONTROL GUIDELINES {#acm212272-sec-0003}
===============================================

In order to comprehensively assess brachytherapy remote afterloader performance, additional guideline tests, as outlined in related CPQR Technical Quality Control (TQC) guidelines, must also be completed and documented, as applicable. Related TQC guidelines, available at <http://www.cpqr.ca/programs/technical-quality-control/>, include: Safety Systems[19](#acm212272-bib-0019){ref-type="ref"}Major Dosimetry Equipment[20](#acm212272-bib-0020){ref-type="ref"}Treatment Planning Systems[21](#acm212272-bib-0021){ref-type="ref"}

4. TEST TABLES {#acm212272-sec-0004}
==============

4.A. Notes on per treatment tests {#acm212272-sec-0005}
---------------------------------

T1Plan data imported from a treatment planning system into the treatment console should be verified for source strength, dwell positions, and dwell times. In case of many dwell positions, the verification of a sub‐set of positions is acceptable. For a plan already present in the treatment console, the same verification should be made to assure proper plan selectionT2Plan dwell times adjustment by the treatment console for the treatment date should be verified (by an independent calculation: hand calculation, decay factor chart, or software calculation). Action level will depend on the treatment console decay frequency and time resolution; express in percentage of difference and/or in secondT3Minimum dwell time should be verified against the device driven limits. Those limits should take into account both the effect of transit dose and positioning reproducibility. Some remote afterloader systems might have a positioning reproducibility dependence on dwell time. All dwell times should be equal or greater than set limitT4Catheters/applicators connections to remote afterloader indexer channels must match planT5Survey the treatment room and patient to ensure that source has been completely retracted

4.B.. Notes on treatment day (or per treatment for PDR) tests {#acm212272-sec-0006}
-------------------------------------------------------------

D1During source exposure, verify that the non‐emergency interrupt button (if equipped) retracts the source to its safe and shielded positionD2On the treatment console, displays should be verified. At minimum, treatment status indicators should be verified by exposing a source. Indicators could be visual and audible. When a treatment key is available, its deactivation should prevent source expositionD3Remote afterloader console date and time are properly set. Decayed source strength is accurate compared to an independent calculation (hand calculation, decay factor chart or software calculation), taking into account treatment console decay frequencyD4Verify accuracy of source drive mechanism positioning. A visual inspection with a camera is acceptable. Apply also to dummy drive mechanism if used to measure catheter lengthD5Comparison of dwell time accuracy with external standard such as a stopwatch. The dwell time used should be sufficiently long such that errors in the measurement of the time (e.g., reaction time of the observer) are less than 1%

4.C. Notes on quarterly tests {#acm212272-sec-0007}
-----------------------------

Q1Verify the applicators, guide tubes, and connectors are exempt of damage (excessive wear, kinks, etc.)Q2The configuration of this test will depend on the design of the facility and equipment. Safety is the concern and tests should be designed accordingly. The first objective is to verify that the equipment safely retracts the source wire after a power failure. The second objective is to verify that the equipment properly records treatment delivered before power failure and permits to resume the treatment after power recoveryQ3Verify functionality of remote afterloader interlocks related to source and dummy wires. This includes incorrect connection of applicator to transfer guide tube, incorrect connection of transfer guide tube to remote afterloader, and obstructionQ4Verify accuracy of dummy drive mechanism positioning. The purpose is to assure proper obstruction detection by assuring no false positive or false negative obstruction. If dummy drive mechanism is used to measure catheter length for treatment planning, then the action level should be lowered to 1 mmQ5Accuracy of source drive mechanism to be verified. Autoradiographs or ion‐chamber measurements could be used. If visual checks with in‐room cameras are to be used, source positioning in the cable construction should be verified independentlyQ6Comparison of measured source strength with manufacturer supplied value. On installation of a new source, source strength must be measured using calibrated re--entrant chamber and electrometer traceable to a national standards laboratory. The re‐entrant chamber and electrometer should have been calibrated within the last 2 yr. Measured source strength should be used for planning and treatment purposes. Discrepancies greater than 5% between the measured and the manufacturer\'s supplied source strengths must be investigated. This action level could be lowered to 3%[22](#acm212272-bib-0022){ref-type="ref"} if the manufacturer supplied source strength offers such precision. Stability of re‐entrant chamber should be verified prior to use. A second qualified medical physicist should perform a check of the calibrationQ7Visual check on film that the radioactive material is evenly distributed in the encapsulated source. Most important for sources composed of multiple source pelletsQ8Documentation relating to the daily quality control checks, preventive maintenance, service calls, and subsequent checks must be complete, legible, and the operator identified

4.D. Notes on annual tests {#acm212272-sec-0008}
--------------------------

A1Manual emergency hand crank functionality should be verified with manufacturer service engineer. It is desirable that each person responsible to operate the hand crank, in an emergency situation, practices its operation annually when a dummy wire replaces the source wireA2Monitor leakage radiation to check afterloader\'s safe integrity. Intensity of leakage radiation must be lower than the value set by manufacturer and local regulationsA3Verify multichannel indexer functions properly. The wire must be sent to the proper programmed channelA4Comparison of dwell time accuracy with an external standard performed more rigorously than the treatment day testA5Verification of the linearity of the timer over a clinically relevant range. The action level represents deviations of measured values from those calculated using a linear fit to the measured dataA6Reproducibility of transit time effect or transit dose effect or source speed between dwell positions. Can be verified using autoradiographs, ion‐chamber measurements, or visual checks with in‐room cameras. A fixed and reproducible applicator geometry is required to assure the same wire drive speedA7Reusable applicators and transfer guide tubes length should be measured to verify dosimetric lengths if used clinically as nominal values. This measurement could also verify that no debris has come into the lumenA8Verify physical dimensions of reusable applicators and templates (e.g., diameters, angles, shields). They must match dimensions used in the planning processA9Verify shielding integrity of shielded applicators. Visual and radiographic inspections should be performedA10Check x‐ray markers positional accuracy if used clinically for source positioning. If markers are only used to draw the applicator path, then only the integrity should be checkedA11The configuration of this test will depend on the design of the facility and equipment, and local regulations. All staff should review the emergency procedures when a source fails to retract properly and remains outside the safeA12To ensure redundancy and adequate monitoring, a second qualified medical physicist must independently verify the implementation, analysis, and interpretation of the quality control tests at least annuallyA13For PDR only, verify pulse sequencing functionality according to manufacturer\'s recommendations
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DISCLAIMER {#acm212272-sec-0011}
==========

All information contained in this document is intended to be used at the discretion of each individual centre to help guide quality and safety program improvement. There are no legal standards supporting this document; specific federal or provincial regulations and licence conditions take precedence over the content of this document. As a living document, the information contained within this document is subject to change at any time without notice. In no event shall the Canadian Partnership for Quality Radiotherapy (CPQR) or its partner associations, the Canadian Association of Radiation Oncology (CARO), the Canadian Organization of Medical Physicists (COMP), and the Canadian Association of Medical Radiation Technologists (CAMRT), be liable for any damages, losses, expenses, or costs whatsoever arising in connection with the use of this document.
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